Federated Hermes
APRE icon

Federated Hermes’s Aprea Therapeutics APRE Stock Holding History

Federated Hermes’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-113
Closed -$746 – 2115
2022
Q4 		$746 Sell
113
-60
-35% -$633 ﹤0.01% 2067
2022
Q3 		$2K Sell
173
-12
-6% -$213 ﹤0.01% 1958
2022
Q2 		$3K Buy
185
+7
+4% +$161 ﹤0.01% 1935
2022
Q1 		$7K Buy
178
+3
+2% +$123 ﹤0.01% 1913
2021
Q4 		$10K Buy
175
+67
+62% +$5.92K ﹤0.01% 1925
2021
Q3 		$11K Buy
108
+16
+17% +$1.45K ﹤0.01% 1972
2021
Q2 		$9K Buy
92
+88
+2,200% +$8.13K ﹤0.01% 1990
2021
Q1 		$1K Buy
+4
New +$467 ﹤0.01% 2151

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Federated Hermes's APRE Position: Q1 2023 in Review

Federated Hermes sold out of Aprea Therapeutics (APRE) in Q1 2023, closing a stake of 113 shares — an estimated $746 sold.

Federated Hermes first reported a position in APRE in Q1 2021 and held it in 8 quarters. The position peaked at $11K in Q3 2021. 18 funds tracked by Wall St. Rank hold APRE as of Q1 2023.

  • Federated Hermes reported no remaining Aprea Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Federated Hermes sold 113 Aprea Therapeutics shares in Q1 2023, an estimated $746.
  • Federated Hermes first reported a position in Aprea Therapeutics in Q1 2021 and held it in 8 quarters.
  • Federated Hermes's Aprea Therapeutics position peaked at $11K in Q3 2021.
  • 18 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2023.

Based on Federated Hermes's 13F filing for Q1 2023, filed 8 May 2023.